Clinical Trial Update: AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating AV-101 as adjunct antidepressant therapy in patients with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• AV-101

Snippet

Sponsor: VistaGen Therapeutics, Inc. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED